Healthcare analytics firm IQVIA beats Q3 revenue estimates, reaffirms guidance
|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
217.43 USD |
-1.40% |
|
+2.54% | +10.65% |
Published on 10/28/2025
at 07:25 am EDT
Reuters
© Reuters –
2025
| 07:25am |
Healthcare analytics firm IQVIA beats Q3 revenue estimates, reaffirms guidance |
RE |
Oct. 27 |
Earnings calendar for October 27-31: Apple, Microsoft, Amazon, and others report |
 |
Oct. 23 |
Glenmark Pharmaceuticals to Launch Ropivacaine Hydrochloride Injection in November |
MT |
Oct. 20 |
BofA Adjusts Price Target on IQVIA Holdings to $230 From $215 |
MT |
Oct. 18 |
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL ( Single-Dose and Multiple-Dose Vials |
CI |
Oct. 16 |
Deutsche Bank Adjusts Price Target on IQVIA to $235 From $220, Maintains Buy Rating |
MT |
Oct. 13 |
Baird Adjusts IQVIA Holdings Price Target to $224 From $206, Maintains Neutral Rating |
MT |
Oct. 09 |
IQVIA Shares Higher After HSBC Upgrade |
MT |
Oct. 09 |
The Sound of Silence |
|
Oct. 09 |
HSBC Upgrades IQVIA Holdings to Buy From Hold, Adjusts Price Target to $235 From $195 |
MT |
Oct. 09 |
Analysts recommendations: Datadog, Alphabet, AMD, Elevance Health, Tesla… |
|
Oct. 08 |
Leerink Partners Adjusts IQVIA Holdings Price Target to $232 From $222, Maintains Outperform Rating |
MT |
Oct. 08 |
Evercore ISI Adjusts Price Target on IQVIA Holdings to $240 From $220, Maintains Outperform Rating |
MT |
Oct. 07 |
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada |
CI |
Oct. 02 |
Barclays Adjusts Price Target on IQVIA Holdings Inc to $200 From $185, Maintains Equalweight Rating |
MT |
Sep. 15 |
Baird Adjusts IQVIA Holdings Price Target to $206 From $196, Maintains Neutral Rating |
MT |
Sep. 11 |
Mid Wynd underperforms benchmark as Apple and Alphabet detractors |
AN |
Sep. 10 |
Iqvia launches ai-powered clinical trial financial suite for integrated management |
RE |
Sep. 10 |
Iqvia Announces Launch of Clinical Trial Financial Suite, A Next-Generation Platform for Integrated Financial Management |
CI |
Sep. 09 |
Iqvia Shares Rise After Jefferies Upgrade |
MT |
Sep. 09 |
Jefferies Upgrades IQVIA Holdings to Buy From Hold, Raises Price Target to $225 From $195 |
MT |
Sep. 04 |
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension |
CI |
Sep. 03 |
Rothschild & Co Redburn Adjusts PT on IQVIA Holdings to $214 From $228, Maintains Buy Rating |
MT |
Sep. 02 |
Iqvia announces CFO transition in early 2026 |
RE |
Sep. 02 |
IQVIA Holdings Inc. Announces Chief Financial Officer Changes, Effective February 28, 2026 |
CI |
IQV: Dynamic Chart
Iqvia Holdings Inc. is one of the world’s leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
– development of contract research and clinical development solutions and services (55.4%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
– development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
– integrated services (4.7%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (47.8%), Europe and Africa (31.9%) and Asia/Pacific (20.3%).
More about the company
Buy
Last Close Price
217.43USD
Average target price
223.42USD
Spread / Average Target
+2.76%
Consensus
Select your edition
All financial news and data tailored to specific country editions
link
